Effect of cognitive-existential group therapy on survival in early-stage breast cancer

David W. Kissane, Anthony Love, Allison Hatton, Sidney Bloch, Graeme Smith, David M. Clarke, Patricia Miach, Jill Ikin, Nadia Ranieri, Raymond D. Snyder

Research output: Contribution to journalArticleResearchpeer-review

112 Citations (Scopus)

Abstract

Purpose: Cognitive-existential group therapy (CEGT) was developed to improve mood and mental attitude toward cancer in women with early-stage breast cancer receiving adjuvant chemotherapy. Given the debate about group therapy's association with increased survival in women with metastatic breast cancer, we were curious to check its effect at a much earlier stage in the cancer journey. Patients and Methods: We randomly assigned 303 women with early-stage breast cancer who were receiving adjuvant chemotherapy to either 20 sessions of weekly group therapy plus three relaxation classes (n = 154) or to a control condition of three relaxation classes alone (n = 149). The primary outcome was survival. Results: CEGT did not extend survival; the median survival time was 81.9 months (95% CI, 64.8 to 99.0 months) in the group-therapy women and 85.5 months (95% CI, 67.5 to 103.6 months) in the control arm. The hazard ratio for death was 1.35 (95% CI, 0.76 to 2.39; P = .31). In contrast, histology and axillary lymph node status were significant predictors of survival. Low-grade histology yielded a hazard ratio of 0.342 (95% CI, 0.17 to 0.69), and axillary lymph node-negative status yielded a hazard ratio of 0.397 (95% CI, 0.20 to 0.78). Conclusion: CEGT does not prolong survival in women with early-stage breast cancer.

Original languageEnglish
Pages (from-to)4255-4260
Number of pages6
JournalJournal of Clinical Oncology
Volume22
Issue number21
DOIs
Publication statusPublished - 1 Dec 2004

Cite this

Kissane, David W. ; Love, Anthony ; Hatton, Allison ; Bloch, Sidney ; Smith, Graeme ; Clarke, David M. ; Miach, Patricia ; Ikin, Jill ; Ranieri, Nadia ; Snyder, Raymond D. / Effect of cognitive-existential group therapy on survival in early-stage breast cancer. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 21. pp. 4255-4260.
@article{e10e6918da0a4b61846800d5f6845ce5,
title = "Effect of cognitive-existential group therapy on survival in early-stage breast cancer",
abstract = "Purpose: Cognitive-existential group therapy (CEGT) was developed to improve mood and mental attitude toward cancer in women with early-stage breast cancer receiving adjuvant chemotherapy. Given the debate about group therapy's association with increased survival in women with metastatic breast cancer, we were curious to check its effect at a much earlier stage in the cancer journey. Patients and Methods: We randomly assigned 303 women with early-stage breast cancer who were receiving adjuvant chemotherapy to either 20 sessions of weekly group therapy plus three relaxation classes (n = 154) or to a control condition of three relaxation classes alone (n = 149). The primary outcome was survival. Results: CEGT did not extend survival; the median survival time was 81.9 months (95{\%} CI, 64.8 to 99.0 months) in the group-therapy women and 85.5 months (95{\%} CI, 67.5 to 103.6 months) in the control arm. The hazard ratio for death was 1.35 (95{\%} CI, 0.76 to 2.39; P = .31). In contrast, histology and axillary lymph node status were significant predictors of survival. Low-grade histology yielded a hazard ratio of 0.342 (95{\%} CI, 0.17 to 0.69), and axillary lymph node-negative status yielded a hazard ratio of 0.397 (95{\%} CI, 0.20 to 0.78). Conclusion: CEGT does not prolong survival in women with early-stage breast cancer.",
author = "Kissane, {David W.} and Anthony Love and Allison Hatton and Sidney Bloch and Graeme Smith and Clarke, {David M.} and Patricia Miach and Jill Ikin and Nadia Ranieri and Snyder, {Raymond D.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1200/JCO.2004.12.129",
language = "English",
volume = "22",
pages = "4255--4260",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "AMER SOC CLINICAL ONCOLOGY",
number = "21",

}

Effect of cognitive-existential group therapy on survival in early-stage breast cancer. / Kissane, David W.; Love, Anthony; Hatton, Allison; Bloch, Sidney; Smith, Graeme; Clarke, David M.; Miach, Patricia; Ikin, Jill; Ranieri, Nadia; Snyder, Raymond D.

In: Journal of Clinical Oncology, Vol. 22, No. 21, 01.12.2004, p. 4255-4260.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Effect of cognitive-existential group therapy on survival in early-stage breast cancer

AU - Kissane, David W.

AU - Love, Anthony

AU - Hatton, Allison

AU - Bloch, Sidney

AU - Smith, Graeme

AU - Clarke, David M.

AU - Miach, Patricia

AU - Ikin, Jill

AU - Ranieri, Nadia

AU - Snyder, Raymond D.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Purpose: Cognitive-existential group therapy (CEGT) was developed to improve mood and mental attitude toward cancer in women with early-stage breast cancer receiving adjuvant chemotherapy. Given the debate about group therapy's association with increased survival in women with metastatic breast cancer, we were curious to check its effect at a much earlier stage in the cancer journey. Patients and Methods: We randomly assigned 303 women with early-stage breast cancer who were receiving adjuvant chemotherapy to either 20 sessions of weekly group therapy plus three relaxation classes (n = 154) or to a control condition of three relaxation classes alone (n = 149). The primary outcome was survival. Results: CEGT did not extend survival; the median survival time was 81.9 months (95% CI, 64.8 to 99.0 months) in the group-therapy women and 85.5 months (95% CI, 67.5 to 103.6 months) in the control arm. The hazard ratio for death was 1.35 (95% CI, 0.76 to 2.39; P = .31). In contrast, histology and axillary lymph node status were significant predictors of survival. Low-grade histology yielded a hazard ratio of 0.342 (95% CI, 0.17 to 0.69), and axillary lymph node-negative status yielded a hazard ratio of 0.397 (95% CI, 0.20 to 0.78). Conclusion: CEGT does not prolong survival in women with early-stage breast cancer.

AB - Purpose: Cognitive-existential group therapy (CEGT) was developed to improve mood and mental attitude toward cancer in women with early-stage breast cancer receiving adjuvant chemotherapy. Given the debate about group therapy's association with increased survival in women with metastatic breast cancer, we were curious to check its effect at a much earlier stage in the cancer journey. Patients and Methods: We randomly assigned 303 women with early-stage breast cancer who were receiving adjuvant chemotherapy to either 20 sessions of weekly group therapy plus three relaxation classes (n = 154) or to a control condition of three relaxation classes alone (n = 149). The primary outcome was survival. Results: CEGT did not extend survival; the median survival time was 81.9 months (95% CI, 64.8 to 99.0 months) in the group-therapy women and 85.5 months (95% CI, 67.5 to 103.6 months) in the control arm. The hazard ratio for death was 1.35 (95% CI, 0.76 to 2.39; P = .31). In contrast, histology and axillary lymph node status were significant predictors of survival. Low-grade histology yielded a hazard ratio of 0.342 (95% CI, 0.17 to 0.69), and axillary lymph node-negative status yielded a hazard ratio of 0.397 (95% CI, 0.20 to 0.78). Conclusion: CEGT does not prolong survival in women with early-stage breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=13144275570&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.12.129

DO - 10.1200/JCO.2004.12.129

M3 - Article

C2 - 15452189

AN - SCOPUS:13144275570

VL - 22

SP - 4255

EP - 4260

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -